Acute neuritis and persistent pain are the most significant clinical manifestations of herpes zoster and are end points for clinical trials therapy. In an acyclovir and prednisone study, patients were categorized according to pain severity and number of lesions at presentation. Risk categories were defined according to the magnitude of risk ratios (RRs) and a comparison of Kaplan-Meier survival estimates. For acute neuritis and zoster-associated pain, RRs defined rate of resolution. Patients who presented with severe or incapacitating pain and a large number of lesions were less likely to achieve resolution of both acute neuritis and zosterassociated pain (RR, 18.0; 95% confidence interval [CI], 6.6-48.6, and RR, 5.3; 95% CI, 4.2-17.2, respectively). These analyses identify the subgroups of patients for whom aggressive interventions are most strongly indicated.
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Herpes zoster (or shingles) results from the reactivation of latent varicella-zoster virus from the dorsal root ganglia. Although herpes zoster is not a reportable disease, an estimated 300,000-500,000 cases occur annually in the United States [1] . In immunocompetent persons, the most notable manifestations of shingles are acute neuritis (pain occurring within 30 days of disease onset) and persistent pain, traditionally termed postherpetic neuralgia. Clinical trials of acyclovir [2] [3] [4] [5] , valacyclovir [6] , and famciclovir [7, 8] have demonstrated that antiviral therapy accelerates the healing of cutaneous lesions and ameliorates pain caused by herpes zoster. The increased risk of postherpetic neuralgia in older patients was established by Hope-Simpson [9] over 30 years ago and has been confirmed in many subsequent studies [10] . In addition, observations by our group and others have suggested that severity of disease at presentation may also predict risk for prolonged pain [11] [12] [13] .
In a study of acyclovir and prednisone therapy for herpes zoster that used a randomized factorial design [14] , pain 2 ϫ 2 was serially assessed during the first month of enrollment (acute neuritis) and as a continuum extending from study enrollment through 6 months of follow-up (zoster-associated pain). In the study population of relatively healthy patients 150 years of age, pain and quality of life end points (which included return to usual activity, ability to sleep uninterrupted, and cessation of analgesic use) were evaluated as a function of treatment and other covariates. Based on a stepwise Cox regression model, two covariates predicted the times to resolution of acute neuritis and zoster-associated pain. Symptoms resolved significantly faster in patients with no or mild pain at baseline than in those with severe or incapacitating pain. Similarly, patients who had the fewest lesions at enrollment had accelerated rates of resolution of acute and long-term pain. These variables significantly predicted resolution of herpes zoster pain, independent of the effects of treatment. The present study defined risk categories for achieving cessation of acute and long-term pain and for returning to 100% usual activity. These risk categories better define the natural history of herpes zoster among immunocompetent patients and identify groups who should be targeted for intensive therapy.
Methods
Study population. The population in this report comprised immunocompetent adults у50 years of age who presented with a localized dermatomal vesicular rash that was clinically consistent with herpes zoster and had been present р72 h. Inclusion and exclusion criteria have been described previously [14] . In total, 201 evaluable patients, equally distributed among the 4 treatment regimens, were available for analysis.
Patients received one of the following regimens for 21 days: acyclovir plus prednisone, acyclovir plus prednisone placebo, prednisone plus acyclovir placebo, or placebos for both acyclovir and prednisone. Acyclovir was administered orally (800 mg 5 times/day for 21 days). Prednisone was administered orally at 60 mg/day for days 1-7, 30 mg/day for days 8-14, and 15 mg/day for days 15-21.
End points. The primary end points were persistence of pain at 1 and 6 months of follow-up and assessments of quality of life as measured by return to 100% usual activity. Pain was assessed daily during the first month after enrollment and monthly thereafter. Each patient was asked to rate pain as none, mild, moderate, severe, or incapacitating. Analgesic use was recorded and correlated with pain severity. Patient activity was evaluated daily during the first month and monthly thereafter. Patients reported whether they were unable to perform normal activity or if they had resumed 25%, 50%, or 100% of their usual activity.
Data assessment. In order to define risk groups, patients were grouped on the basis of two covariates: pain severity and number of lesions at baseline. Pain severity was divided into three levels: none or mild, moderate, or severe or incapacitating. Number of lesions at baseline was divided into three categories: р20, 21-46, or у47 based on the distribution of this variable in the entire study population. Patients were then classified into 9 subgroups on the basis of these two variables. Risk ratios (RRs) for cessation of acute neuritis were calculated for each patient subgroup. The RRs represent the rate of pain resolution for each patient subgroup. Thus, the larger the RR, the lower the risk for prolonged pain. Patient subgroups with RRs of similar magnitude were collapsed together. Kaplan-Meier survival estimates were then calculated for time to cessation of acute neuritis for each patient group with varying magnitudes of RRs and compared by the log-rank test. The final risk categories were defined as those patient groups with different magnitudes of RRs and those whose survival estimates were significantly different. A similar procedure was used for defining risk groups for time to cessation of zoster-associated pain and for time to return to 100% usual activity. Table 1 shows patient characteristics and the distributions of pain severity and number of lesions at baseline for the 4 treatment groups. Slightly 150% of the patients were women, and 30% of subjects were from minority groups. The median age was 61 years, and the age by decade was well distributed among treatment groups. Patients randomized to the placebo group presented with slightly more severe pain (83% with moderate or severe pain) compared with the other 3 treatment groups. Those in the acyclovir plus prednisone group had the next highest moderate or severe pain (74.5%), followed by the prednisone-only (66%) and the acyclovir-only (62.5%) groups. The differences among the 4 treatment groups, however, were not statistically significantly different (
Results

Patient Demographics
). The number of P ϭ .110 lesions at baseline was equally distributed across the 4 treatment groups, (table 1) . P ϭ .410
Risk Categories
Acute neuritis. Figure 1A shows the 9 patient subgroups by pain severity and number of lesions at baseline. Among the 57 patients with no or mild pain at baseline, 16 (28%) had р20 lesions, 27 (47%) 21-46 lesions, and 14 (24%) had у47 lesions. Seventy-one subjects experienced moderate pain at baseline, of ratio. risk whom 23 (32%), 11 (15%), and 37 (52%) had р20, 21-46, and у47 lesions, respectively. The remaining 73 patients experienced severe or incapacitating pain at baseline, of whom 19%, 23%, and 58% had р20, 21-46, and у47 lesions, respectively. The RRs for acute neuritis in the 9 subgroups ranged from 1.0 to 18.0 ( figure 1A) .
From the magnitude of these RRs, 4 risk groups for cessation of acute neuritis could be derived on the basis of pain severity and number of lesions at baseline. Patients with no or mild pain and р20 lesions at baseline resolved acute neuritis most quickly and were placed in risk group 1 ( ; 95%
; 95% CI, 1.01-5.9), and severe or incapacitating pain RR ϭ 2.4 and у47 lesions at baseline (risk group 4:
). Eight RR ϭ 1.0 percent of the subjects were placed in the lowest risk group and 25%, 46%, and 21% were in risk groups 2, 3, and 4, respectively. There was no significant difference in the distribution of treatment groups within each of the 4 risk groups (x 2 test, P ϭ ), showing that the differences in risk among the categories .651 was not due to an imbalance of treatment distribution among the risk categories. Figure 2 shows Kaplan-Meier survival estimates for the 4 risk categories based on pain severity and number of lesions at baseline. Patients with no or mild pain and р20 lesions at baseline had acute pain resolve more quickly than those in risk groups 2 ( ), 3 ( ), and 4 ( ). Patients who P ϭ .002 P ! .001 P ! .001 had severe or incapacitating pain and у47 lesions at baseline took longer to resolve acute pain than those in the other 3 risk groups (all pairwise log-rank test, ). The median times P ! .05 to resolution of acute neuritis were 7, 22, 27, and у28 days for patients in risk groups 1, 2, 3, and 4, respectively. Thus, 50% of patients in risk group 4 had acute pain beyond 28 days versus 7 days for risk group 1.
The RRs for resolution of acute neuritis by each risk category for each of the 4 drug treatment groups were further estimated. Despite smaller sample sizes when the population was sorted into treatment groups, certain patterns were evident. The individual RRs from the acyclovir and prednisone, acyclovir-only, and placebo groups did not vary significantly from the overall RR. For example, the overall RR in risk group 3 was 2.4 (95% CI, 1.01-5.9), while the treatment-specific RRs for risk group 3 were 1.1, 2.1, and 3.1 for acyclovir and prednisone, acyclovironly, and placebo, respectively. The RR for risk group 3 in the prednisone-only group was slightly elevated ( ) com-RR ϭ 4.6 pared with the overall RR. Further, the rate of acute pain resolution was not slower in the placebo group compared with patients in nonplacebo groups.
Zoster-associated pain. RRs for cessation of zoster-associated pain ranged from 1.0 to 13.1 ( figure 1B ). Based on these RRs, 3 risk categories were identified for cessation of zosterassociated pain based on severity and number of lesions at baseline. Patients with no or mild pain and !47 lesions at baseline resolved zoster-associated pain the most quickly (risk group 1; RR, 8.5; 95% CI, 4.2-17.2). Most patients (58%) were categorized as risk group 2, which included those with no or mild pain and у47 lesions, those with moderate pain regardless of number of lesions, and those with severe or incapacitating pain and !47 lesions at baseline (RR, 3.8; 95% CI, 1.9-7.3). As with acute neuritis, risk group 3 included patients with severe or incapacitating pain and у47 lesions at baseline (RR, 1.0). Figure 3 shows the Kaplan-Meier survival curves for the 3 risk categories for cessation of zoster-associated pain. Patients in risk group 1 achieved the fastest resolution of long-term pain, with a median time to resolution of zoster-associated pain of 15 days. In contrast, the median times to resolution of zosterassociated pain were 73 and 1180 days among patients in risk Figure 5 . Time to return to 100% usual activity by severity of pain and no. of lesions at baseline at 1 month of follow-up groups 2 and 3, respectively. Similar to the acute neuritis end point, there was no significant difference in the distribution of the 4 treatment groups within each of the 3 categories (x 2 test, ). P ϭ .250
The RRs were similar for the acyclovir and prednisone, acyclovir-only, and placebo groups and slightly elevated in the prednisone-only group when compared with the overall RR. For example, the treatment-specific RRs for risk group 2 were 2.4, 5.5, 9.9, and 2.2 in the combined, acyclovir-only, prednisone-only, and placebo groups, respectively, compared with an overall RR of 3.8 (95% CI, 1.9-7.3). Unlike patients with acute neuritis, those given placebo appeared to resolve zoster-associated pain more slowly than subjects in the active treatment groups.
Quality of Life: Return to Usual Activity
One month after enrollment, 3 risk groups were identified for time to return to usual activity, based on the magnitude of the RRs (figure 4A). Risk group 1 was defined as patients with no or mild pain regardless of number of lesions (RR, 5.2; 95% CI, 3.2-8.3), risk group 2 as persons with moderate pain regardless of number of lesions or with severe or incapacitating pain and р20 lesions (RR, 2.2; 95% CI, 1.4-3.5), and risk group 3 as patients with severe or incapacitating pain with у21 lesions (RR, 1.0). Of these patients, 28%, 42%, and 29% were in groups 1-3, respectively. Figure 5 shows that patients in risk group 1 returned to usual activity faster than those in risk groups 2 or 3 ( for P ! .001 each). The median times to return to 100% usual activity for the 3 risk categories were 1, 8, and 25 days, respectively. Similar patient risk categories were evident for return to 100% usual activity at 6 months of follow-up ( figure 4B ). Patients with severe or incapacitating pain and у21 lesions were less likely to achieve return to normal activity (risk group 3: RR, 1.0). Persons with moderate pain, regardless of number of lesions, or those with severe or incapacitating pain and р20 lesions were categorized as risk group 2 (RR, 2.1; 95% CI, 1.4.-3.1), while those with no or mild pain were least likely to have impaired activity 6 months after enrollment (risk group 1: RR, 3.7; 95% CI, 2.4-5.6).
The RRs by treatment groups for return to normal activity both at 1 and 6 months of follow-up did not vary widely from the overall RR. Further, the placebo group did not appear to have a slower rate of return to normal activity than the nonplacebo groups.
Discussion
These analyses define clinical characteristics that predict the natural history of herpes zoster in immunocompetent patients. Utilizing a Cox regression model, the severity of pain and the number of lesions at baseline clearly established the risk for prolonged duration of pain. The effect of these two disease characteristics varied for acute neuritis and zoster-associated pain. For acute neuritis, we identified 4 risk groups that, when prospectively assessed, predicted the rapidity of pain resolution. In patients who presented with the fewest lesions and the least pain, acute neuritis resolved the most promptly. In contrast, patients with more lesions (у21) and with moderate, severe, or incapacitating pain had significantly prolonged time to resolution of acute pain. Similarly, for the zoster-associated pain end point, 3 risk groups were identified that correlated with resolution of pain. Again, large number of lesions and more severe pain at the initial clinical evaluation predicted prolonged duration of pain. Taken together, patients who presented with more severe pain and more lesions took the longest to resolve both acute and chronic pain.
Careful assessment of the data indicates that these two baseline clinical characteristics more strongly influenced resolution of acute pain than long-term pain. For example, among patients with moderate pain and р20 lesions at baseline, accelerated resolution of acute neuritis was apparent compared with patients with severe or incapacitating pain. However, this differential effect was lost over the ensuing 5 months. Such analyses select out patients with severe pain and the largest numbers of lesions as the group at greatest risk for persistent pain.
In addition to pain resolution, we assessed risk groups for the ability to return to usual activity. Here a larger proportion of patients was placed in the lowest risk groups. Nevertheless, persons with severe or incapacitating pain and у21 lesions at baseline remained at the greatest risk for inability to return to usual activity.
Despite smaller sample sizes, similar patterns of pain resolution and return to normal activity were observed by treatment group. This implies that severity of pain and number of lesions at baseline affect these outcomes over and above the effect of antiviral and prednisone therapy. These analyses were based on a clinical trial that utilized 21 days of acyclovir therapy, which is longer than the conventional course (7-10 days). We cannot infer from our data that a shorter course of acyclovir therapy would have resulted in the same treatment outcomes. Nevertheless, other well-designed clinical trials of herpes-zoster therapy have shown no advantage of treatment beyond 7 days [15, 16] . The optimal duration of concomitant corticosteroid administration has not been defined.
Similar to the findings from our earlier study [14] , a significant correlation was observed between analgesic use and risk groupings. For example, among those at greatest risk for acute neuritis, most (89%) reported taking some form of analgesic compared with only 32% among those in the lowest risk group ( ). Similarly, a significant correlation was observed be-P ! .01 tween analgesic use and risk grouping for resolution of zosterassociated pain.
A few caveats are in order about these assessments. First, the identification of risk groups requires both the evaluation of pain severity and number of lesions at baseline. Second, when assessing the quality of life end point of return to usual activity, removal of pain in the Cox regression model did not exclude this parameter as influencing long-term outcome. Stated differently, return to usual activity was influenced by more than pain and its change over time. Finally, in the creation of the risk groups, the categorization of patients according to number of lesions was somewhat arbitrary, being derived from a distribution of lesion number in the entire study population.
The knowledge derived from these analyses will affect the design of future clinical trials in the evaluation of patients with herpes zoster. While of benefit, current treatment of herpes zoster with acyclovir, valacyclovir, or famciclovir does not completely eliminate the most significant clinical problems, pain and essential quality of life issues. Consequently, alternative therapeutic approaches may need to be considered for persons at highest risk, identified here as patients with the most severe pain and the most lesions. For these persons, intervention with concomitant corticosteroid therapy appears indicated to improve acute neuritis and normal activity outcomes after 1 month of treatment. Other modalities to reduce pain, such as early initiation of tricyclic antidepressants, need to be evaluated.
